These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21187731)

  • 1. Bilateral intravitreal injection of antivascular endothelial growth factor therapy.
    Mahajan VB; Elkins KA; Russell SR; Boldt HC; Gehrs KM; Weingeist TA; Stone EM; Abràmoff MD; Liu D; Folk JC
    Retina; 2011 Jan; 31(1):31-5. PubMed ID: 21187731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy.
    Lima LH; Zweifel SA; Engelbert M; Sorenson JA; Slakter JS; Cooney MJ; Klancnik JM; Yannuzzi LA; Freund KB
    Retina; 2009 Oct; 29(9):1213-7. PubMed ID: 19934815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilateral simultaneous intravitreal injections in the office setting.
    Bakri SJ; Risco M; Edwards AO; Pulido JS
    Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
    Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A; Stinnett S; Fekrat S
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
    Małgorzata F
    Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
    Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
    Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study.
    Fong DS; Custis P; Howes J; Hsu JW
    Ophthalmology; 2010 Feb; 117(2):298-302. PubMed ID: 19969368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular events in patients with age-related macular degeneration treated with intraocular bevacizumab.
    Sheybani A; Kymes S; Schlief S; Apte R
    Retina; 2009; 29(10):1404-8. PubMed ID: 19898178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
    Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
    Retina; 2006; 26(9):994-8. PubMed ID: 17151485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study.
    French DD; Margo CE
    Retina; 2011 Jun; 31(6):1036-42. PubMed ID: 21836410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration.
    Zweifel SA; Engelbert M; Khan S; Freund KB
    Retina; 2009; 29(10):1527-31. PubMed ID: 19898185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.
    Adelman RA; Zheng Q; Mayer HR
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):105-10. PubMed ID: 20187807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
    Ronan SM; Yoganathan P; Chien FY; Corcóstegui IA; Blumenkranz MS; Deramo VA; Elner SG; Fastenberg DA; Johnson MW; López M; Mateo C; Moshfeghi DM; Navarro R; Rosenblatt BJ; Sanislo SR; Saxe SJ; Zacks DN
    Retina; 2007 Jun; 27(5):535-40. PubMed ID: 17558313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?
    Schaal S; Kaplan HJ; Tezel TH
    Ophthalmology; 2008 Dec; 115(12):2199-205. PubMed ID: 18930553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.
    Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ
    Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.
    Fintak DR; Shah GK; Blinder KJ; Regillo CD; Pollack J; Heier JS; Hollands H; Sharma S
    Retina; 2008; 28(10):1395-9. PubMed ID: 18827737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.